Señales en vivo de AEZS | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 16:00):

Stats
Volumen de hoy	5 884.00
Volumen promedio	4 692.00
Capitalización de mercado	9.70M
EPS	$0 ( 2024-03-28 )
Próxima fecha de ganancias	( $-0.810 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.590
ATR14	$0.133 (1.66%)

Aeterna Zentaris Inc Correlación

10 Correlaciones Más Positivas
FDMT	0.971
FTXG	0.968
KIDS	0.964
CTKB	0.964
ACCD	0.962
SANA	0.961
UAL	0.961
STKS	0.961
VIAV	0.96
FMHI	0.959

10 Correlaciones Más Negativas
MTRX	-0.957
XLRN	-0.944
ATRS	-0.942
GXII	-0.939
KSICU	-0.939
EACPU	-0.938
HERA	-0.938
MURFU	-0.937
HNRG	-0.936
ZING	-0.936

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aeterna Zentaris Inc Finanzas

Annual	2023
Ingresos:	$4.58M
Beneficio Bruto:	$4.18M (91.31 %)
EPS:	$-3.47

FY	2023
Ingresos:	$4.58M
Beneficio Bruto:	$4.18M (91.31 %)
EPS:	$-3.47

FY	2022
Ingresos:	$5.64M
Beneficio Bruto:	$5.48M (97.22 %)
EPS:	$-7.76

FY	2021
Ingresos:	$5.26M
Beneficio Bruto:	$5.17M (98.29 %)
EPS:	$-1.750

Financial Reports:

No articles found.

Aeterna Zentaris Inc

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.